The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...

Researchers have demonstrated the efficacy of a compact, specific and AAV-compatible CRISPR-Cas13 variant, Cas13bt3, for RNA-targeted gene therapy...

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.